MYGN
Myriad Genetics, Inc. Healthcare - Diagnostics & Research Investor Relations →
Myriad Genetics, Inc. (MYGN) closed at $4.54 as of 2026-06-19, trading 70.4% below its 200-week moving average of $15.35. This places MYGN in the extreme value zone. The stock moved further from the line this week, up from -72.0% last week. The 14-week RSI sits at 49, indicating neutral momentum.
Trading volume is running at 0.9x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.73 ratio) is neutral — neither side is clearly dominating.
Over the past 1554 weeks of data, MYGN has crossed below its 200-week moving average 28 times. On average, these episodes lasted 29 weeks. The average one-year return after crossing below was -10.8%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $429 million, MYGN is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -23.5%. The stock trades at 1.3x book value.
Share count has increased 15.1% over three years, indicating dilution.
Over the past 29.8 years, a hypothetical investment of $100 in MYGN would have grown to $80, compared to $1824 for the S&P 500. MYGN has returned -0.7% annualized vs 10.2% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: MYGN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MYGN Crosses Below the Line?
Across 28 historical episodes, buying MYGN when it crossed below its 200-week moving average produced an average return of -11.8% after 12 months (median -16.0%), compared to +14.0% for the S&P 500 over the same periods. 39% of those episodes were profitable after one year. After 24 months, the average return was -11.6% vs +32.3% for the index.
Each line shows $100 invested at the moment MYGN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. MYGN currently has negative free cash flow, so price-based dislocation levels are not available. The score still tracks yield deviation from baseline.
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from MYGN's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
MYGN has crossed below its 200-week MA 28 times with an average 1-year return of +-10.8% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 1996 | Jan 1997 | 18 | 13.3% | -2.6% | -18.3% |
| Apr 1997 | Jun 1997 | 7 | 22.8% | +4.0% | -7.9% |
| Jun 1997 | Nov 1999 | 124 | 68.9% | -43.6% | -27.2% |
| Sep 2001 | Oct 2001 | 2 | 17.1% | -43.3% | -61.6% |
| Feb 2002 | Sep 2005 | 184 | 76.9% | -70.8% | -70.1% |
| Feb 2010 | Feb 2010 | 1 | 3.0% | -11.0% | -78.7% |
| May 2010 | May 2011 | 53 | 37.0% | +29.7% | -74.1% |
| Jun 2011 | Feb 2012 | 37 | 24.1% | +4.3% | -80.0% |
| Mar 2012 | Apr 2012 | 4 | 6.2% | +10.6% | -80.1% |
| May 2012 | Jul 2012 | 5 | 6.5% | +39.7% | -80.2% |
| Oct 2013 | Oct 2013 | 1 | 1.9% | +65.8% | -80.1% |
| Dec 2013 | Jan 2014 | 1 | 9.1% | +63.3% | -78.6% |
| Jun 2016 | Sep 2017 | 65 | 51.3% | -29.0% | -85.3% |
| Oct 2017 | Nov 2017 | 2 | 9.8% | +35.0% | -84.0% |
| Mar 2018 | May 2018 | 8 | 11.0% | +11.5% | -85.0% |
| Nov 2018 | Mar 2019 | 18 | 15.0% | -23.4% | -85.3% |
| May 2019 | Jul 2019 | 12 | 24.8% | -47.9% | -83.8% |
| Aug 2019 | Oct 2019 | 9 | 27.2% | -50.1% | -82.1% |
| Nov 2019 | Jan 2021 | 64 | 61.4% | -39.6% | -80.8% |
| Apr 2021 | Apr 2021 | 1 | 2.0% | -12.2% | -83.4% |
| May 2021 | Jun 2021 | 4 | 2.0% | -18.3% | -83.4% |
| Nov 2021 | Jul 2022 | 35 | 36.6% | -26.2% | -82.9% |
| Aug 2022 | May 2023 | 41 | 39.3% | -31.2% | -81.7% |
| Jun 2023 | Jun 2023 | 1 | 0.3% | +6.6% | -80.0% |
| Jul 2023 | Feb 2024 | 30 | 36.8% | +17.4% | -79.8% |
| Mar 2024 | May 2024 | 8 | 18.6% | -52.4% | -78.5% |
| Jun 2024 | Jun 2024 | 1 | 2.4% | -77.0% | -79.5% |
| Oct 2024 | Ongoing | 88+ | 81.9% | Ongoing | -80.6% |
| Average | 29 | — | +-10.8% | — |
Frequently Asked Questions
Is MYGN below its 200-week moving average?
Yes. As of 2026-06-19, Myriad Genetics, Inc. (MYGN) is trading 70.4% below its 200-week moving average of $15.35. The current price is $4.54.
What is MYGN's 200-week moving average price?
Myriad Genetics, Inc.'s 200-week moving average is $15.35 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when MYGN drops below its 200-week moving average?
MYGN has crossed below its 200-week moving average 28 times in our data. The average one-year return after these crossings was -10.8%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 29 weeks on average.
Is MYGN a good value right now?
Here's what our data says about MYGN as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 49. Free cash flow is currently negative. Return on equity is -23.5%. Price-to-book is 1.3x. This is not a buy or sell recommendation — always do your own research.
How does MYGN compare to the S&P 500?
Over the past 29.8 years, $100 invested in MYGN would have grown to $80, compared to $1824 for the S&P 500. That's -0.7% annualized vs 10.2% for the index. MYGN has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19